Treatment of acne vulgaris using blue light photodynamic therapy in an African-American patient.(Case study)Terrell, Shaundre; Aires, Daniel; Schweiger, Eric S. ABSTRACT Background: Studies indicate photodynamic therapy is an effective treatment of inflammatory acne lesions on patients with Fitzpatrick skin types 1-3. There is a lack of evidence in the literature regarding the use of photodynamic therapy to treat acne vulgaris in African American patients. This article reports the first case of blue light photodynamic therapy to treat moderate inflammatory facial acne on an African American patient with type 5 skin. Observations: This article describes a 26-year-old African American woman with moderate inflammatory facial acne vulgaris. On examination, she had over 15 inflammatory papules on her face and post-inflammatory hyperpigmentation. The patient had a history of treatment failure with the following therapies: topical benzoyl peroxide, topical antibiotics, topical retinoids and oral antibiotics. At presentation, the patient was using a combination topical benzoyl peroxide/clindamycin product in the morning and tazoratene gel in the evening without success. The patient was treated with 20% aminolevulinic acid/blue-light photodynamic therapy spaced monthly for a total of four treatments, a once-daily application of hydroquinone 4% cream and her existing topical regimen. The patient reported significant improvement of inflammatory acne lesions and post-inflammatory hyperpigmentation following two treatments with photodynamic therapy and was virtually clear of all acne lesions after the third treatment. Conclusion: Photodynamic therapy is an emerging remedy for patients with acne vulgaris resistant to standard treatment, particularly in patients with skin of color who are more sensitive to post-inflammatory hyperpigmentation. In this African-American patient, 20% aminolevulinic acid/blue-light photodynamic therapy was effective in treating facial acne vulgaris. INTRODUCTION Acne vulgaris is a prevalent skin disease that affects the majority of teenagers and many adults. (1) Often an inflammatory condition, acne is characterized by impaction of the pilosebaceous unit, keratinocyte hyperproliferation and Propionibacterium acnes (P. acnes) colonization. Acne frequently leads to social, psychological and emotional distress, particularly for patients who continue to suffer from the condition throughout adulthood. CASE REPORT A 26-year-old African American woman with Fitzpatrick skin type 5 skin presented with acne vulgaris. The patient reported a history of facial acne for the past several years that was ineffectively managed with topical benzoyl peroxide, topical antibiotics, topical retinoids and oral antibiotics. She expressed frustration with the failure of previous therapies and was concerned with the residual dark spots that remained for months following acne lesion resolution. At presentation, the patient was being treated with a combination topical benzoyl peroxide/clindamycin product in the morning and tazoratene gel in the evening. The regimen had been utilized for several months without relief. On physical examination, the patient had over 15 inflammatory papules on her face, as well as many areas of post-inflammatory hyperpigmentation. Photodynamic therapy was initiated. The patient’s existing topical regimen was continued throughout photodynamic therapy. Additionally, a once-daily application of hydroquinone 4% cream was started two weeks prior to the first photodynamic therapy and continued throughout the entire course of treatment. The patient received a total of four photodynamic therapy treatments, each spaced monthly. An acetone scrub preceded application of 20% aminolevulinic acid (Kerastic[R], DUSA) which was incubated for 60 minutes. Subsequently, the patient’s face was irradiated with blue light (BLU-U[R], DUSA). She received 6 minutes of irradiation during the initial treatment and 9 minutes of irradiation during the three succeeding visits. The patient tolerated the therapy well, although she reported moderate warmth during the procedure. Following therapy, the patient applied sunscreen (SPF 30) on her face and was advised to avoid the sun for 48 hours. The patient reported peeling 5-7 days after treatment and darkening of the skin up to two weeks following each treatment. Subsequent to the second treatment, the patient reported significant improvement of inflammatory acne lesions and postinflammatory hyperpigmentation. Following three treatments, the patient was almost completely clear of all acne lesions. She remained virtually free of acne up to the final follow-up visit, which was one month after the fourth photodynamic treatment. DISCUSSION Acne vulgaris is a common skin condition that affects people of all ages and skin colors. Inflammation is often a component of acne. indeed, inflammatory papules in patients with darker skin tones can lead to such sequelae as hyperpigmentation and scarring. (6) Many African-American patients, including this patient, present with concomitant acne vulgaris and acne-induced post-inflammatory hyperpigmentation. In fact, hyperpigmentation and scarring associated with acne vulgaris is more prevalent in dark-complected skin than light-complected skin. Hyper-pigmented macules are often more distressing to the patient than the acne itself. Therefore, early and effective treatment of acne in patients with dark-complected skin is important in preventing hyperpigmentation and scarring. (7) Photodynamic therapy with 20% aminolevulinic acid and intense pulsed light (IPL) produced an 87.7% reduction (p CONCLUSION In summary, the positive therapeutic outcome in our patient suggests that blue light photodynamic therapy may be a safe and effective treatment option for acne vulgaris in African-American patients. Further investigation is warranted to confirm these results. Moreover, additional study is needed to determine optimal photosensitizer incubator times, light sources and treatment frequency in all patient populations. Shaundre Terrell has no financial interests to report. REFERENCES
|
Copyright 2009. Eric S. Schweiger, M.D. All Rights Reserved.